Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

This Analyst Is Bullish on Repligen's FlexBiosys Acquisition for Fluid Management Portfolio

Published 12/04/2023, 21:23
Updated 12/04/2023, 22:40
© Reuters.  This Analyst Is Bullish on Repligen's FlexBiosys Acquisition for Fluid Management Portfolio
RGEN
-

Benzinga -

  • Repligen Inc (NASDAQ: RGEN) agreed to acquire FlexBiosys Inc to build its Fluid Management franchise and add a full range of single-use bioprocessing bags and assemblies.
  • The exact terms of the deal were not disclosed, but Repligen will acquire for cash and equity consideration.
  • William Blair writes that despite not closing any M&A deals in 2022, Repligen has a strong record of doing small tuck-ins to fill in gaps in the product portfolio, and FlexBiosys adds to recent fluid management deals.
  • Also Read: Despite Attractive End Markets, Analyst Outlines Concerns For Repligen Stock.
  • The analyst writes that management believes the custom nature of FlexBiosys’ bags is a point of differentiation in a market with several much larger competitors.
  • William Blair notes that FlexBiosys’ base business is expected to be roughly flat in 2023, given ongoing destocking headwinds, although management anticipates 25% growth in 2024 and onward.
  • The deal expands Repligen’s single-use fluid management offering, adds in-house manufacturing capabilities, and should enable more vertical integration and supply chain control to the broader portfolio.
  • The deal is expected to be accretive to adjusted EPS in 2024.
  • Price Action: RGEN shares closed higher by 5.46% at $179.70 on Wednesday.
Latest Ratings for RGEN DateFirmActionFromTo
Feb 2022SVB LeerinkMaintainsOutperform
Oct 2021SVB LeerinkMaintainsOutperform
Oct 2021Exane BNP ParibasInitiates Coverage OnOutperform
View More Analyst Ratings for RGEN

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.